Levsin®/SL tablets (hyoscyamine sulfate tablets USP) contain 0.125 mg hyoscyamine sulfate formulated for sublingual administration. However, the tablets may be chewed or taken orally.
Levsin®/SL is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids.
Levsin®/SL is effective as adjunctive therapy in the treatment of peptic ulcer. It can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps. May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis. For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders. Also used as adjunctive therapy in the treatment of neurogenic bladder and neurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon). Also used in the treatment of infant colic (elixir and drops). Levsin®/SL is indicated along with morphine or other narcotics in symptomatic relief of biliary and renal colic; as a drying agent in the relief of symptoms of acute rhinitis; in the therapy of parkinsonism to reduce rigidity and tremors and to control associated sialorrhea and hyperhidrosis. May be used in the therapy of poisoning by anticholinesterase agents.
Published Studies Related to Levsin (Hyoscyamine)
Sublingual hyoscyamine spray as premedication for colonoscopy: a randomized double-blinded placebo-controlled trial. [2008.07]
BACKGROUND: Colonic motility and spasm during colonoscopy may affect duration and quality of the examination as well as patient comfort during and after the procedure. Previous studies assessing the utility of antispasmodic agents in colonoscopy demonstrated conflicting results. The aim of this study was to determine the effect of sublingual hyoscyamine spray (IB-Stat, Inkine Pharmaceutical) on the performance of colonoscopy... CONCLUSIONS: Procedural difficulty and colonic motility scores were significantly lower in subjects who received sublingual hyoscyamine before colonoscopy.
Sublingual L-hyoscyamine for duodenal antimotility during ERCP: a prospective randomized double-blinded study. [2007.10]
BACKGROUND: ERCP is often made difficult by duodenal motility. Glucagon is typically used to inhibit this motility. L-hyoscyamine is an antimuscarinic, anticholinergic agent shown to be a feasible intravenous alternative to glucagon. OBJECTIVE: Demonstrate whether pre-ERCP sublingual L-hyoscyamine reduces the amount of glucagon required to complete ERCP... CONCLUSIONS: Preprocedure administration of sublingual L-hyoscyamine did not reduce the amount of glucagon required to complete ERCP.
Clinical Trials Related to Levsin (Hyoscyamine)
RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem [Recruiting]
The Trident Tritanium acetabular component of a total hip prosthesis is a new developed
uncemented acetabular component. In this randomized controlled trial (RCT) the tritanium cup
will be compared with the Trident HA acetabular component in two equal sized groups. The
Symax HA coated stem will be used as femoral component in both groups.
- The primary objective is to determine the prosthetic migration of the uncemented
acetabular and femoral total hip components using model based RSA technique
- Secondary objectives are on one hand to assess clinical outcome on the other hand
assessing patient satisfaction in both groups using Harris Hip Score, Oxford Hip Score,
WOMAC, and EQ-5D questionnaires
- Tertiary objective is to assess bone remodeling of the uncemented acetabular components
and the HA-coated Symax hip stem using QCT derived from usinf F18-fluoride PET in a
cohort of 12 consecutive patients of this RCT
A total of 50 patients will be enrolled in this RCT divided into two equal groups. Patients
have to fulfill the inclusion and exclusion criteria.
All evaluations will be done pre-operatively with 2 weeks before surgery, and after surgery
at 4 weeks, 3 and 6 months and 1 and 2 years.